Search results
Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of...
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is...
Nektar Therapeutics (NASDAQ:NKTR shareholders incur further losses as stock declines 11% this week,...
Simply Wall St. via Yahoo Finance· 2 years agoWhile it may not be enough for some shareholders, we think it is good to see the Nektar Therapeutics...
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Zacks via Yahoo Finance· 10 months agoNektar Therapeutics NKTR reported a loss of 27 cents per share for the second quarter of 2023, which...
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Simply Wall St. via Yahoo Finance· 4 months agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR)...
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Given the large stake in the stock by institutions, Nektar Therapeutics' stock price...
Will Nektar Therapeutics (NASDAQ:NKTR) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 9 months agoJust because a business does not make any money, does not mean that the stock will go down. For...
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
Simply Wall St. via Yahoo Finance· 1 year agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks via Yahoo Finance· 2 years agoNektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings...
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar...
Zacks via Yahoo Finance· 1 year agoCatalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and...
Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel
Simply Wall St. via Yahoo Finance· 1 year agoYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Nektar Therapeutics (NASDAQ:NKTR)...